Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Genotype analysis of HHT patients in China and bevacizumab for refractory epistaxis
ChiCTR2100043253Phase 4Recruiting
- Sponsor
- Shandong Second People's Hospital
- Start
- Feb 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of bevacizumab in hereditary hemorrhagic telangiectasia (HHT), sponsored by Shandong Second People's Hospital. Primary endpoints: Blood routine examination, Nosebleed and 1 more. Started Feb 2021; status: recruiting.
02
Drugs
bevacizumab
03
Conditions
hereditary hemorrhagic telangiectasia (HHT)
Beyond the preview
Go deeper on ChiCTR2100043253.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100043253.